Present Title and Affiliation

CURRICULUM VITAE Macus T. Kuo, Ph.D. PRESENT TITLE AND AFFILIATION Primary Appointment Felix L. Hass Professor in Basic Science, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX Dual/Joint/Adjunct Appointment N/A CITIZENSHIP United States HOME ADDRESS 3520 Plumb Street Houston, TX 77005 OFFICE ADDRESS The University of Texas MD Anderson Cancer Center Department of Translational Molecular Pathology 2130 W. Holcombe Blvd, Houston, Texas 77030 Unit Number: Unit 951 Room Number: LSP9.4206 Phone: (713) 834-6038 Fax: (713) 834-6084 Email: [email protected] EDUCATION Degree-Granting Education National Taiwan University, Taipei, Taiwan, BS, 1968, Plant Pathology National Taiwan University, Taipei, Taiwan, MS, 1971, Plant Pathology The University of Texas, Graduate School of Biomedical Sciences at Houston, Houston, TX, PHD, 1973, Molecular Biology Macus T. Kuo, Ph.D.

Postgraduate Training Project Investigator, Department of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1973−1/1976 CREDENTIALS Board Certification N/A Licensures Active N/A Inactive N/A EXPERIENCE/SERVICE Academic Appointments Research Associate, Department of Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/1976−8/1979 Visiting Researcher, Faculte' de Medecine, Laboratoire de Genetique Moleculaires des Eukaryotes, Center National de la Recherche Scientifique, Strasburg, France, 9/1978−8/1979 Assistant Biologist and Assistant Professor of Biology, Department of Cell Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/1979−9/1983 Member, The University of Texas Health Science Center, Graduate School of Biomedical Sciences, Houston, TX, 9/1980−present Visiting Scholar, Department of Biological Sciences, Stanford University, Palo Alto, CA, 5/1982−9/1982 Associate Professor of Pathology (Biology) and Associate Biologist (Pathology), Division of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/1983−8/1993 Professor, Department of Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1993−present Felix L. Hass Professor in Basic Science, Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1997−present Administrative Appointments/Responsibilities

of 32 Macus T. Kuo, Ph.D.

Chief, Section of Eukaryotic Cell Research, Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/1986−1/1999 Other Appointments/Responsibilities N/A Endowed Positions Felix L Haas Professorship in Basic Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1997 Consultantships N/A Military or Other Governmental Service Chinese 1st NCO Academy, Chuang,-Li, Taiwan, Member, 1/1968−1/1969 Institutional Committee Activities Recombinant DNA Subcommittee, Member, 1/1981−1/1983 Institutional Research Grant Committee, Reviewer, 1/1981−1/1986 Research Committee, Member, 1/1983−1/1984 DNA Sequence Core Facility, Member, 1/1993−present Faculty Senate Special Program Committee, Member, 1/1994 Basic Research Achievement Award Selection Committee, Member, 1/1996 Alfred Knudson Outstanding Dissertation Award Committee, Member, 1/1997 Distinguished Scholar and Postdoctoral Fellowship Odyssey, Member, 1/1999 Faculty Senate Representative, Member, 1/2000−1/2006 Study Section Committee, Cancer Discovery Program, Member, 1/2000 CCSG Core Resources, DNA Analysis Facility, Member, 2004−present

Study Section, Sister Institute Research Grant Application, Member, 2011−2013 Scientific Publications Advisory Board, Member, 2012−present HONORS AND AWARDS Sigma XI Awards, 1973 US-France Exchange (NIH-INSERM) Scientist, 1978 Dean's Excellence Awards, GSBS, 1998 Guest Professor, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan, 2006 Guest Professor, National Cheng Kung University, Tainan, Taiwan, 2007 Member, Elite Project, National Applied Research Laboratories, Taiwan, 2007−2008 Grants and Contracts Funded Principal Investigator, 16%, Mechanism of Resistance to Arginine Deiminase Therapy in Advance Melanoma, 1 R01-CA152197, NIH/NCI, 9/17/2010−7/31/2014, $990,513 ($238,864/year) Principal Investigator, 24%, Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy, 1-R01- CA149260, NIH/NCI, 9/23/2010−4/30/2015, $1,037,500 ($207,500/year) Pending N/A Other N/A Completed Principal Investigator, Action of Antitumor Drugs on Chromatin Structure, CD-25, American Cancer Society (ACS), 1979−1981, $189,450 Principal Investigator, Chromosome Structure and Gene Arrangement, NIGMS R01 GM28573, National Institutes of General Medical Sciences, 1/1/1981−12/1/1989, $653,973 ($128,000/year) Principal Investigator, Action of Antitumor Drugs on Chromatin Structure, G-831, The Robert A. Welch Foundation, 1/1/1984−1/1/1990, $150,000 ($25,000/year)

Principal Investigator, Gene Expression in Multidrug Resistant Cells, NCI R01 CA4362l, NIH/NCI, 1/1/1987−1/1/1991 ($87,000/year) Principal Investigator, Expression of the Multidrug-Resistance Gene in Transgenic Animals, 15-058, Texas Higher Education Board, 1/1/1990−1/1/1992, $138,100 ($69,050/year) Principal Investigator, Molecular Cloning of Gene Encoding Single-Strand-Sequence-Specific-DNA- Binding Proteins, 15-095, Texas Higher Education Board, 1/1/1990−1/1/1992, $150,624 ($75,312/year) Co-Principal Investigator, m-AMSA Resistance and Expression of p76 protein, NCI R01 CA51207, NIH/NCI, PI - M. Beran, 1/1/1990−1/1/1993, $210,380 ($69,310/year) Principal Investigator, Hepatocarcinogenesis and Drug Resistance Gene Expression, NCI R01 CA56848, NIH/NCI, 1/1/1992−1/1/1996, $445,487 ($118,273/year) Principal Investigator, Regulation of mdr1 Gene Expression in Liver and Uterus, NCI R01 CA55813, NIH/NCI, 1/1/1992−1/1/1996, $453,426 ($107,324/year) Principal Investigator, Hepatic Gene Therapy Using a Novel Receptor, NIDDK R01 DK49091, National Institute of Diabetes and Digestive and Kidney Diseases, 1/1/1994−1/1/1997, $245,358 ($78,600/year) Principal Investigator, Regulation of mdr Gene Expression in Liver Cancers, R01 CA72404-01, NCI, 5/9/1997−4/30/2000, $395,707 Principal Investigator, Redox Regulation of Multidrug Resistance Gene Expression, R01 CA79085-01, NIH/NCI, 8/1/1999−7/31/2003, $464,849 Co-Principal Investigator, "A phase II chemoprevention study of colorectal ACF screening, regression and prevention in high risk patients," My project: "Roles of redox sensitive genes in colorectal cancer progression," NO1-CN-05125, NIH/NCI, PI - Frank Sinicrope, M.D., 9/1/2000−12/31/2003, $102,000 ($51,000/year) Principal Investigator, Regulation of mdr Gene Expression in Liver Cancers, R01 CA72404-03S1, NIH/NCI, 1/1/2001−1/1/2002, $41,480 Principal Investigator, 5%, Regulation of mdr Gene Expression in Liver Cancers, 2 R01 CA72404, NIH/NCI, 9/1/2001−8/31/2007, $747,000 ($186,750/year) Principal Investigator, 25%, Targeted Prodrug Therapy of Liver Cancers, 5 R01 CA95003-04, NIH/NCI, 9/1/2002−8/31/2008, $712,000 ($178,000/year) Principal Investigator, 5%, Genomic Instability and Evolution of Drug Resistance, 5 R01 CA89541-04, NIH/NCI, 4/1/2004−2/28/2011, $937,920 ($187,584/year) Principal Investigator, Redox Regulation of Multidrug Resistance Gene Expression, NCI 5 R01 CA79085- 07, NIH/NCI, 6/16/2006−4/30/2010, $743,590 ($148,718/year) Co-Principal Investigator, Targeted Therapy of Malignant Melanoma Using Engineered Human Arginase, The Center for Targeted Therapy and the Texas Institute of Drug and Diagnostic Development, 11/1/2008−10/31/2010, $50,000 ($25,000/year) Not Funded

Protocols Funded N/A

Unfunded N/A Patents and Technology Licenses Patents The University of Texas M. D. Anderson Cancer Center, Macus T. Kuo, Ph.D. "Targeted nucleic acid delivery into liver cells," United States, 5,766,899, Issued The University of Texas M. D. Anderson Cancer, Macus T. Kuo, Ph.D. Prodrug Therapy of Liver Diseases Using Receptor-Mediated Delivery of Malarial Circumsporozoite Protein as a Carrier," United States, 10/515,547, Pending Technology Licenses N/A Grant Reviewer/Service on Study Sections Review Committee, National Science Foundation, Reviewer, 1981 Review Committee, National Science Foundation, Reviewer, 1983 NIH, Experimental Therapeutics-1 Study Section, ad hoc member, 1986 NIH, Minority Biomedical Research Support Program Grant Review Committee, ad hoc member, 1986 NIH, Special Review Committee for P0-1, Yale University, 1987 Review Committee, National Science Foundation, Reviewer, 1987 Site Visit Team, Program Project grant application (submitted by Stanford University Medical School, NIH, Member, 1988 Site Visit Team, Cancer Center Grant, Albert Einstein College of Medicine, Bronx, New York, NIH, Member, 1990 Site Visit Team, Cancer Center Grant, Jackson Laboratory, Bay Harbor, ME, NCI, Member, 1991 Experimental Therapeutics-1 Study Section, NIH, Ad Hoc Member, 1994−1996 Experimental Therapuetics-1 Study Section, NIH, Member, 1996−2000 NIH, Member, Biological and Physiological Sciences Special Study Section, 1997 NIH, Special Review Committee for R13 grants (Support of Scientific Meetings), 1998 NIH, Experimental Therapeutic-2, Special Study Section, 1998 NIH, Hematology, Special Study Section, NIH, Reviewer, 1999 RGC Research Grants Council, Hong Kong, China, ad hoc Reviewer, 2001−2003 Experimental Therapeutics-1 Study Section, NIH, Ad Hoc Member, 2001 Experimental Therapeutics-1 Study Section, NIH, Ad Hoc Member, 2002 NIH, Clinical Oncology Study Section, ad hoc Reviewer, 2002 Basic Molecular Cancer Therapy Study Section, NIH, Member, 2004 A*Star Biomedical Research Council, Singapore, ad hoc Reviewer, 2005−2006 Rapid Access to Intervention Development Study Section, NIH, Member, 2005 Florida Biomedical Research Program, Florida State, NIH, Ad Hoc Member, 2007 Developmental Therapeutics Program, Rapid Access to NCI Discovery Resources (R*A*N*D) grant application, NCI, Member, 2008 Breast Cancer Champaign Research Grant, United Kingdom and Republic of Ireland, Reviewer, 2009 Center for Scientific Review, Basic Mechanisms of Cancer Therapeutics Study Section, NIH, Reviewer, 2010 Basic Molecular Cancer Therapy, NIH, Ad Hoc Member, 2010 Lung Cancer, British Lung Cancer Association, Grant Reviewer, 2011 National Medical Research Council, Singapore, NMRC, Reviewer, 2011 Research, Research Grant Council Hong Kong, Grant Reviewer, 2012. National Medical Research Council, Singapore, NMRC, Reviewer, 2013 Israel Science Foundation, Reviewer, 2013 NIH, ZCA1 SRLB-C (J1) Provocative Questions-Cancer Therapy & Outcomes, November, 2013

PUBLICATIONS Peer-Reviewed Original Research Articles 1. Haidle CW, Weiss KK, Kuo MT. Release of free bases from deoxyribonucleic acid after reaction with bleomycin. Mol Pharmacol 8(5):531-7, 9/1972. 2. Haidle CW, Kuo MT, Weiss KK. Nucleic acid specificity of bleomycin. Biochem Pharmacol 21:3308- 12, 12/1972. 3. Kuo MT, Wu LC. Base compositions of deoxyribonucleic acid isolated from mushrooms. Mushroom Sci. (London) 8:l44-l5l, 1972. 4. Kuo MT, Wu LC. The studies of deoxyribonucleic acid and their application in chemotoxonomy. Scientific Agriculture (Taiwan) 20:l-23, 1972. 5. Kuo MT, Haidle CW, Inners LD. Characterization of bleomycin resistant DNA. Biophys. J. 13:1296- l306, 1973. 6. Kuo MT, Hsu TC, Saunders GF. In situ RNA synthesis in fixed mammalian chromosomes. Exp Cell Res 88(2):424-7, 10/1974. 7. Kuo MT, Haidle CW. Characterization of chain breaks in DNA induced by bleomycin. Bioch. Biophys. Acta. 355:109-114, 1974. 8. Kuo MT, Meinke W, Saunders GF. Localization of cytoplasmic-membrane-associated DNA in human chromosomes. Proc Natl Acad Sci U S A 72(12):5004-6, 12/1975. 9. Kuo MT, Ried ME, Saunders GF. Abundancy and diversity of mRNA sequences in human leukocytes. Differentiation 5(2-3):175-8, 6/1976. 10. Kuo MT, Sahasrabuddhe CG, Saunders GF. Presence of messenger specifying sequences in the DNA of chromatin subunits. Proc. Natl. Acad. Sci. USA 73:l572-l575, 1976. 11. Kuo MT, Auger LT, Saunders GF, Haidle CW. Effect of bleomycin on the synthesis and function of RNA. Cancer Res 37(5):1345-8, 5/1977. 12. Yunis JJ, Kuo MT, Saunders GF. Localization of sequences specifying messenger RNA to light- staining G-bands of human chromosomes. Chromosoma 61(4):335-44, 6/1977. 13. Kuo MT, Saunders GF. Location of messenger specifying sequences in mammalian chromosomes. Chromosoma 63(3):241-52, 9/1977. 14. Watt MW, Kuo MT, Arrighi FE. Genome analysis of Peromyscus (Rodentia, Cricetidae) VII. Localization of satellite DNA sequences and cytoplasmic poly (A) RNA sequences on Peromyscus on chromosomes. Chromosoma 64:l33-l42, 1977. 15. Kuo MT, Hsu TC. Bleomycin causes release of nucleosomes from chromatin and chromosomes. Nature 271(5640):83-4, 1/1978. 16. Kuo MT, Hsu TC. Studies in heterochromatin DNA: characterization of transcripts synthesized in situ from C-banded preparations. Chromosoma 65(4):325-34, 2/1978. 17. Kuo MT, Samy TS. Effects of neocarzinostatin on mammalian nuclei: release of nucleosomes. Biochim Biophys Acta 518(1):186-90, 3/1978. 18. Kuo MT, Hsu TC. Biochemical and cytological studies in bleomycin actions on chromatin and chromosomes. Chromosoma 68:229-240, 1978. 19. Kuo MT. Studies in heterochromatin DNA: accessibility of late replicating heterochromatin DNA in chromatin to micrococcal nuclease digestion. Chromosoma 70(2):183-94, 1/1979. 20. Kuo MT, Mandel JL, Chambon P. DNA methylation: correlation with DNase I sensitivity of chicken ovalbumin and conalbumin chromatin. Nucleic Acids Res 7(8):2105-13, 12/1979. 21. Bellard M, Kuo MT, Dretzen G, Chambon P. Differential nuclease sensitivity of the ovalbumin and beta-globin chromatin regions in erythrocytes and oviduct cells of laying hen. Nucleic Acids Res 8(12):2737-50, 6/1980. 22. Kuo MT. Altered gel electrophoretic mobility of bleomycin-mediated release of nucleosomal DNA. Cancer Res 41(6):2433-8, 6/1981. 23. Kuo MT. Preferential damage of active chromatin by bleomycin. Cancer Res 41(6):2439-43, 6/1981. 24. Chuang CR, Dott PJ, Kuo MT. Inverted repetitive sequences on human DNA. Proceedings of 14th International Congress of Genetics 3:34-37, 1981. 25. Kuo MT. Distribution of tightly bound proteins in the chicken ovalbumin gene region. Biochemistry 21(2):321-6, 1/1982.

26. Kuo MT. Comparison of chromosomal structures isolated under different conditions. Exp Cell Res 138(1):221-9, 3/1982. 27. Kuo MT. Analysis of DNA attached to the chromosome scaffold. J Cell Biol 93(2):278-84, 5/1982. 28. Kuo MT, Iyer B, Schwarz RJ. Condensation of chromatin into chromosomes preserves an open configuration but alters the DNase I hypersensitive cleavage sites of the transcribed gene. Nucleic Acids Res 10(15):4565-79, 8/1982. 29. Kuo MT, Pathak S, Ramagli L, Rodriguez L, and Hsu TC. Vincristine-resistant Chinese hamster ovary cells. In "Gene Amplification" (ed. Robert T. Schmike). Cold Spring Harbor Laboratory:53-57, 1982. 30. Li S, Meistrich ML, Brock WA, Hsu TC, Kuo MT. Isolation and preliminary characterization of the synaptonemal complex from rat pachytene spermatocytes. Exp Cell Res 144(1):63-72, 3/1983. 31. Kuo MT, Iyer B, Wu JR, Lapeyre JN, Becker FF. Methylation of the alpha-fetoprotein gene in productive and nonproductive rat hepatocellular carcinomas. Cancer Res 44(4):1642-7, 4/1984. 32. Kuo MT. Localization of messenger RNA-specifying sequences to the human Y chromosome. Am J Hum Genet 36(4):932-4, 7/1984. 33. Kuo MT, Sen S, Teeter L, Cailleau RM, Knesek JE, Bowen J. Expression of endogenous murine leukemia virus in transplantable tumor cells and DNA methylation of the viral sequences. Cancer Res 44(8):3518-21, 8/1984. 34. Kuo MT, Plunkett W. Nick-translation of metaphase chromosomes: in vitro labeling of nuclease- hypersensitive regions in chromosomes. Proc Natl Acad Sci U S A 82(3):854-8, 2/1985. 35. Stone EM, Rothblum KN, Alevy MC, Kuo TM, Schwartz RJ. Complete sequence of the chicken glyceraldehyde-3-phosphate dehydrogenase gene. Proc Natl Acad Sci U S A 82(6):1628-32, 3/1985. 36. Sen S, Siciliano MJ, Johnston DA, Schwartz RJ, Kuo T. The expression and chromatin structure of the chicken glyceraldehyde-3-phosphate dehydrogenase gene in mouse cells. J Biol Chem 260(5):3071-8, 3/1985. 37. Teeter LD, Atsumi S, Sen S, Kuo T. DNA amplification in multidrug, cross-resistant Chinese hamster ovary cells: molecular characterization and cytogenetic localization of the amplified DNA. J Cell Biol 103(4):1159-66, 10/1986. 38. Teeter LD, Sanford JA, Sen S, Stallings RL, Siciliano MJ, Kuo MT. Multidrug-resistant phenotype cosegregates with an amplified gene in somatic cell hybrids of drug-resistant Chinese hamster ovary cells and drug-sensitive murine cells. Mol Cell Biol 6(12):4268-73, 12/1986. 39. Sun YL, Pao CI, Sen S, Kuo T. High-resolution mapping of DNase I hypersensitive site in the chicken beta-tubulin gene transfected into monkey cells. J Biol Chem 262(16):7764-9, 6/1987. 40. Dekmezian R, Chen X, Kuo T, Ordonez N, Katz RL. DNA hybridization for human papillomavirus (HPV) in cervical lesions. Relationship of the presence of various viral subtypes to expression of HPV structural proteins, involucrin, and carcinoembryonic antigen. Arch Pathol Lab Med 111(1):22-7, 1987. 41. Sen S, Teeter LD, Kuo T. Specific gene amplification associated with consistent chromosomal abnormality in independently established multidrug-resistant Chinese hamster ovary cells. Chromosoma 95(2):117-25, 1987. 42. Mukhopadhyay T, Batsakis JG, Kuo MT. Expression of the mdr (P-glycoprotein) gene in Chinese hamster digestive tracts. J Natl Cancer Inst 80(4):269-75, 4/1988. 43. Mukhopadhyay T, Kuo MT. Expression of the P-glycoprotein gene in multidrug-resistant Chinese hamster ovary cells. Anticancer Res 9(3):575-8, 5/1989. 44. Sen S, Hittelman WN, Teeter LD, Kuo MT. Model for the formation of double minutes from prematurely condensed chromosomes of replicating micronuclei in drug-treated Chinese hamster ovary cells undergoing DNA amplification. Cancer Res 49(23):6731-7, 12/1989. 45. Kacinski BM, Yee LD, Carter D, Li D, Kuo MT. Human breast carcinoma cell levels of MDR-1 (P- glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumor progesterone receptor content. Cancer Commun 1(1):1-6, 1989. 46. Teeter LD, Becker FF, Chisari FV, Li DJ, Kuo MT. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 10(11):5728-35, 11/1990.

47. Teeter LD, Petersen DD, Nebert DW, Kuo MT. Murine mdr-1, mdr-2, and mdr-3 gene expression: no coinduction with the Cyp1a-1 and Nmo-1 genes in liver by 2,3,7,8-tetrachlorodibenzo-p-dioxin. DNA Cell Biol 10(6):433-41, 7/1991. 48. Teeter LD, Eckersberg T, Tsai Y, Kuo MT. Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ 2(9):429-37, 9/1991. 49. Ikeguchi M, Teeter LD, Eckersberg T, Ganapathi R, Kuo MT. Structural and functional analyses of the promoter of the murine multidrug resistance gene mdr3/mdr1a reveal a negative element containing the AP-1 binding site. DNA Cell Biol 10(9):639-49, 11/1991.

50. Teeter LD, Chan JY, Kuo MT. Coordinate activation of multidrug-resistance (P-glycoprotein) genes mdr2 and mdr3 during mouse liver regeneration. Mol Carcinog 4(5):358-61, 1991. 51. Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J. Relationship between expression of P- glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol 39(1):1-8, 1991. 52. Zou CP, Van NT, Kuo MT. Isolation and characterization of putative intrinsic multidrug resistant Chinese hamster ovary cells by fluorescence activated cell sorting. Anticancer Res 12(2):427-32, 3/1992. 53. Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 261:1222-30, 6/1992. 54. Kuo MT, Zhao JY, Teeter LD, Ikeguchi M, Chisari FV. Activation of multidrug resistance (P- glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ 3(8):531-40, 8/1992. 55. Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133(2):521-8, 8/1993. 56. Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Becker FF, Kuo MT. Activation of distinct multidrug- resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog 8(2):67-73, 1993. 57. Teeter LD, Hsu HC, Curley S, Tong M, Kuo MT. Expression of MDR1 and MDR2 in human hepatocellular carcinoma and liver metastases of colorectoral carcinoma. Inter. J. Oncol. 2:73-80, 1993. 58. Kuo MT, Teeter LD, Curley S, Hsu H-C. Expression of multidrug resistance (P-glycoportein) gene and liver cancers. J. Gasteroentol. Hepatol. 8:17-20, 1993. 59. Kuo MT. Expression of multidrug-resistance (P-glycoprotein) genes in liver cancers: a molecular example of the convergence theory of hepatocarcinogenesis? Mol Carcinog 7(2):73-5, 1993. 60. Kimura O, Yamaguchi Y, Gunning KB, Teeter LD, Husain F, Kuo MT. Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas. Hum Gene Ther 5(7):845-52, 7/1994. 61. Kuo MT, Vyas RC, Jiang LX, Hittelman WN. Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. Mol Cell Biol 14(8):5202-11, 8/1994.

62. Curley SA, Newman RA, Dougherty TB, Fuhrman GM, Stone DL, Mikolajek JA, Guercio S, Guercio A, Carrasco CH, Kuo MT, et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1(5):389-99, 9/1994. 63. Zhao JY, Savaraj N, Song R, Priebe W, Kuo MT. Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicin. Anticancer Res 14(5A):1735-42, 9/1994. 64. Savaraj N, Lampidis TJ, Zhao JY, Wu CJ, Teeter LD, Kuo MT. Two multidrug-resistant Friend leukemic cell lines selected with different drugs exhibit overproduction of different P-glycoproteins. Cancer Invest 12(2):138-44, 1994. 65. Ding ZM, Cristiano RJ, Roth JA, Takacs B, Kuo MT. Malarial circumsporozoite protein is a novel gene delivery vehicle to primary hepatocyte cultures and cultured cells. J Biol Chem 270(8):3667-76, 2/1995. 66. Kuo MT, Julian J, Husain F, Song R, Carson DD. Regulation of multidrug resistance gene mdr1b/mdr1 expression in isolated mouse uterine epithelial cells. J Cell Physiol 164(1):132-41, 7/1995. 67. Yamaguchi Y, Kuo MT. Functional analysis of aryl hydrocarbon receptor nuclear translocator interactions with aryl hydrocarbon receptor in the yeast two-hybrid system. Biochem Pharmacol 50(8):1295-302, 10/1995. 68. Song R, Ikeguchi M, Zhou G, Kuo MT. Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter. J Biol Chem 270(43):25468-74, 10/1995. 69. Ishikawa T, Akimaru K, Kuo MT, Priebe W, Suzuki M. How does the MRP/GS-X pump export doxorubicin? J Natl Cancer Inst 87(21):1639-40, 11/1995. 70. Bao JJ, Zhang WW, Kuo MT. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Hum Gene Ther 7(3):355-65, 2/1996. 71. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271(25):14981-8, 6/1996. 72. Kuo MT, Bao JJ, Curley SA, Ikeguchi M, Johnston DA, Ishikawa T. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 56(16):3642-4, 8/1996. 73. Zhou G, Song R, Kuo MT. A novel cis-acting element is involved in the promoter activity of the rat mdr1b gene. Cell Growth Differ 7(10):1369-81, 10/1996. 74. Akimaru K, Kuo MT, Furuta K, Suzuki M, Noyori R, Ishikawa T. Induction of MRP/GS-X pump and cellular resistance to anticancer prostaglandins. Cytotechnology 19(3):221-7, 1996. 75. Savaraj N, Wu CJ, Xu R, Feun LG, Lampidis TJ, Tapiero H, Kuo MT. Quantitative multidrug resistance associated protein (MRP) gene expression by competitive reverse-transcriptase polymerase chain reaction (RT-PCR). Cellu. Pharmacol. 3:349 - 354, 1996. 76. Ishikawa T, Kuo MT, Priebe W, Suzuki M. RE: How does the MRP/GS-X pump export doxorubicin? Reply. J. Natl. Cancer Inst. 88:467-468, 1996. 77. Wegner CC, Zhou X, Ding ZM, Kuo MT, Carson DD. Tyrosine kinase inhibition decreases Muc-1 expression in mouse epithelial cells. J Cell Physiol 170(2):200-8, 2/1997. 78. Zhou G, Kuo MT. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 272(24):15174-83, 6/1997. 79. Gomi A, Masuzawa T, Ishikawa T, Kuo MT. Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2- chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells. Biochem Biophys Res Commun 239(1):51-6, 10/1997. 80. Gomi A, Shinoda S, Masuzawa T, Ishikawa T, Kuo MT. Transient induction of the MRP/GS-X pump and gamma-glutamylcysteine synthetase by 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2- chloroethyl)-3- nitrosourea in human glioma cells. Cancer Res 57(23):5292-9, 12/1997. 81. Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T, Ishikawa T. Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol 55(5):605-15, 3/1998.

82. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin- glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 247(3):859-63, 6/1998. 83. Zhou G, Kuo MT. Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem 273(25):15387-94, 6/1998. 84. Kuo MT, Sen S, Hittelman WN, Hsu TC. Chromosomal fragile sites and DNA amplification in drug- resistant cells. Biochem Pharmacol 56(1):7-13, 7/1998. 85. Yamane Y, Furuichi M, Song R, Van NT, Mulcahy RT, Ishikawa T, Kuo MT. Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem 273(47):31075-85, 11/1998. 86. Ishikawa T, Kuo MT, Furuta K, Suzuki M. A new aspect on glutathione-associated biological function of MRP/GS-X pump and it gene expression. Cytotechnol. 27:81-93, 1998. 87. Manna SK, Kuo MT, Aggarwal BB. Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor- kappa B and activator protein-1. Oncogene 18(30):4371-82, 7/1999. 88. Furuta K, Tomokiyo K, Kuo MT, Ishikawa T, Suzuki M. Molecular design of glutathione-derived biochemical probes targeting the GS-X pump. Tetrahedron 55:7529-7540, 1999. 89. Ishikawa T, Kuo MT, Furuta K, Suzuki M. The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. Clin Chem Lab Med 38(9):893-7, 9/2000. 90. Bao JJ, Lee BP, Stephens LC, Sahin AA, Van NT, Johnston DA, Ou CN, Kuo MT. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein. Mol Carcinog 29(2):103-11, 10/2000. 91. Ikegami Y, Tatebe S, Lin-Lee YC, Xie QW, Ishikawa T, Kuo MT. Induction of MRP1 and gamma- glutamylcysteine synthetase gene expression by interleukin 1beta is mediated by nitric oxide-related signalings in human colorectal cancer cells. J Cell Physiol 185(2):293-301, 11/2000. 92. Chuang CR, Dott PJ, Kuo MT, Saunders GF. Inverted repetitive sequences on human DNA. Proceedings of l4th International Congress of Genetics 3:34-37, 2000. 93. Deng L, Lin-Lee YC, Claret FX, Kuo MT. 2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem 276(1):413-20, 1/2001. 94. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Tien Kuo M. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol 61(5):555-63, 3/2001. 95. Tatebe S, Sinicrope FA, Kuo MT. Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun 290(5):1427-33, 2/2002. 96. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21(13):1945-54, 3/2002. 97. Lin-Lee YC, Nakamura S, Gandhi V, Curley SA, Stuber D, Burkot TR, Kuo MT. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite- cytosine deaminase fusion protein into liver cancer cells. Mol Cancer Ther 1(7):461-7, 5/2002. 98. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62(17):4903-8, 9/2002. 99. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62(21):6323-8, 11/2002. 100. Tatebe S, Unate H, Sinicrope FA, Sakatani T, Sugamura K, Makino M, Ito H, Savaraj N, Kaibara N, Kuo MT. Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma. Int J Cancer 97(1):21-7, 2002.

101. Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 23(1):173-9, 7/2003. 102. Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT, Ishikawa T. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol 4(3):239- 46, 10/2004. 103. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3(12):1543-9, 12/2004. 104. Song IS, Tatebe S, Dai W, Kuo MT. Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling. J Biol Chem 280(31):28230-40, 8/2005. 105. Wu C, Wangpaichitr M, Feun LG, Kuo MT, Robles C, Lampidis T, and Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in Lung Cancer. Mol Cancer 4:25, 2005. 106. Savaraj N, Wu C, Landy H, Wangpaijit M, Wei Y, Kuo MT, Robles C, Fust AJ, Lampidis T, and Feun L. Procollagen alpha 1 type I: potential aide in hispathological grading of glioma. Cancer Invest 23:577- 581, 2005. 107. Savaraj N, Wei Y, Unate U, Liu P-M, Wu CJ, Wangpaichitr M, Xia D, Xu H-J, Hu S-X, Kuo MT. Redox regulation of matrix metalloproteinase gene family in small cell lung cancer cells. Free Radicals Res 39:373-381, 2005. 108. Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem 281:28122-28130, 9/2006. 109. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26:8191-8201, 11/2006. 110. Kuo MT, Wei Y, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, and Savaraj N. Association of fragile site-associated (FSA) gene expression with epithelial differentiation and tumor development. Biochem Biophy Res Commu 340:887-893, 2006. 111. Wei Y, Lin-Lee YC, Yang X, Dai W, Zhao S, Rassool FV, Elgart GW, Feun L, Savaraj N, and Kuo MT. Molecular cloning of Chinese hamster 1q31 chromosomal fragile site DNA that is important to mdr1 gene amplification reveals a novel gene whose expression is associated with spermatocyte and adipocyte differentiation. Gene 372:44-52, 2006. 112. Kuo MT, and Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog 45:701-709, 2006. 113. Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, Noguchi N, Kuo MT, Ishikawa T. Nrf2- dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. Journal of Experimental Therapeutics and Oncology 6:335-348, 2007. 114. Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, and Feun L. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights 2:119-128, 2007. 115. Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by upregulation of copper transporter hCtr1. Mol Pharmacol 74(3):697-704, 9/2008. e-Pub 6/2008. PMCID: PMC2583459. 116. Aiba I, Hossain A, Kuo MT. Elevated GSH level increases cadmium resistance through downregulation of Sp1-dependent expression of the cadmium transporter ZIP8. Mol Pharmacol 74(3):823- 33, 9/2008. e-Pub 6/2008. PMCID: PMC2574563. 117. Song IS, Chen HH, Aiba I, Hossain A, Liang ZD, Klomp LW, Kuo MT. Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol 74(3):705- 713, 9/2008. e-Pub 5/2008. PMCID: PMC2574735. 118. Wangpaichitr M, Wu C., You M, Kuo MT, Feun L, Lampidis T, Savaraj N. Inhibition of mTOR restores cisplatin sensitivity through downregulation of growth and anti-apoptotic proteins. Euro J Pharmacol 591:124-127, 2008. 119. Liang ZD, Stockton D, Savaraj N, Tien Kuo M. Mechanistic comparison of human cooper transporter hCtr1-mediated transports between copper ion and cisplatin. Mol Pharmacol 76(4):843-853, 10/2009. e-Pub 7/2009. PMCID: PMC2769054.

120. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c- Myc/HIF{alpha}/Sp4. Mol Cancer Ther 8(12):3223-3233, 2009. PMCID: PMC2795119. 121. Guan X, Wang Y, Xie R, Chen L, Bai J, Lu J, Kuo MT. p27Kip1 as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med 14(4):944-953, 4/2010. e-Pub 2/2010. 122. Savaraj N, You M, Wu C, Wangpaichir M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 10:405-412, 2010. 123. You M, Savaraj M, Wangpaichir M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM, Feun L. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun 394:760-766, 2010. 124. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75(2):228-34, 2/2012. e-Pub 7/2011. 125. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 72(18):4616-21, 9/2012. e-Pub 9/2012. PMCID: PMC3445735. 126. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 11(11):2483-94, 11/2012. e-Pub 8/2012. PMCID: PMC3496003. 127. You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem. e-Pub 11/2012. 128. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, Kuo MT. Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells. Cancer Res 72:2622-2633, 2012. 129. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 106:1481-1485, 2012. 130. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming Platinum Resistance Through the Use of a Copper-Lowering Agent. Mol Cancer Ther 11:1221-1225, 2012. 131. Liang ZD, Tsai WB, Lee MY, Savaraj N, Kuo M. Sp1 Oscillation Is Involved in Copper Homeostasis Maintenance by Regulating hCtr1 Expression. Mol Pharmacol 81:455-464, 2012. 132. Wangpaichitr M, Theodoropoulos G, Wu C, You M, Feun L, Kuo MT, Savaraj N. The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells. Mol Cancer Ther 11:604-615, 2012. 133. Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG., Kuo MT. Arginine Deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucse dependence and glutamine addiction. Mol Cancer Therap 2013 (in press). 134. You M, Savaraj N,Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L. Trail induces autophagic protein cleavage through caspase activation in melanoma cells. Mol Cell Biochem 374:181-190, 2013. 135. Chen HHC and Kuo MT. Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. (in press). 136. Liang ZD, Long Y, Chen HHW, Savaraj N, Kuo MT. Regulation of the high affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. J Biol Inorg Chem. (in press).

Invited Articles 1. Sahasrabuddhe CG, Shaw PS, Kuo MT and Saunders GF. Characterization of human chromatin. The Cell Nucleus IV 17:173-193, 1978. 2. Kuo MT. Drug resistance and cancer chemotherapy. Cancer Bulletin 41:5-58, 1989. 3. Talamonti MS, Curley SA, Gallick GE, Teeter LD, and Kuo MT. Development and progression of human colon cancer. Cancer Bull 44:321-326, 1992.

4. Kuo MT, Chen HHW, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 26:71-83, 2/2007. 5. Chan YH, Lee KKH, Chui YL, and Kuo MT. Molecular Studies of HCC, In Hepatocellular Carcinoma, edi by Lau, W.Y. Nova Publication Company, New York, NY:243-277, 2007. 6. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. In "Breast Cancer Chemosensitivity," Yu D and Hung MC (ed). Landes/Eurechls, New York, NY:23-30, 2007. 7. Kuo MT. Roles of multidrug resistance genes in breast cancer resistance. Advance Exp Med Biol 608:23-30, 2007. 8. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Arginine deprivation as a targeted therapy for cancer. Curr Pharmaceut Design 14:1049-1057, 2008. 9. Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 37:833- 862, 2008. 10. Kuo MT. Redox regulation of multidrug resistance in cancer chemotherapy: Molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 11(11):99-134, 1/2009. PMCID: PMC2577715. 11. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 1(4):246-251, 8/2010. PMCID: PMC2998341. 12. Chen HH, Kuo MT. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010:1-7, 2010. e-Pub 9/2010. PMCID: PMC2946579. 13. Chen, H.H.W. Kuo MT. Overcoming platinum drug resistance with copper-lowering agents. AntiCancer Res 33:57-41, 2013

Editorials. N/A Other Articles N/A Abstracts N/A Book Chapters 1. Saunders GF, Haidle CW, Saunders PP, and Kuo MT. Drug-DNA Interaction: Pharmacological basis of cancer chemoterhapy. In: A collection of papers presented at the University of Texas M. D. Anderson Cancer Center Twenty-Ninth Annual Symposium on Fundamental Cancer Research. The Williams and Wilkins Company, 507, 1975. 2. Sharma T, ed. Chromatin structure and gene expression in eukaryotes. In: Advanced Chromosome Studies, 19-38, 1990. 3. Scarpelli DG, Migaki G, and Pletcher JM. Molecular pathogenesis of hepatocellular carcinoma in HBV envelope transgenic mice. In: in Trangenic animal models in biomedical research. 13-18. Armed Forces Institute of Pathology: Washington, DC, 1992. 4. Deng L, Tatebe S, Lin-Lee Y-C, Ishikawa T, and Kuo, MT. MDR and MRP gene family as cellular determinant factors for resistance to clinical anticancer agents. In: Cancer Treat Res. 112, 49-66, 2002. 5. Chan JYH, Lee KKH, Chui YL, Kuo MT. Molecular Aspects. In Hepatocellular Carcinoma. In: World Scientific. Ed(s) Lau WY: New Jersey, USA, 243-277, 2007. 6. Feun, L., Kuo, M. T., You, M., Wu, C. J., Wangpaichitr, M. and Savaraj, N. (2010) Arginine Deiminase and Cancer Therapy, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch9

7. Savaraj N, You M, Wu C, Kuo MT, Dinh V, Wangpaichitr M, Feun L. Targeting Argininosuccinate Synthetase in Cancer Therapy. In: In Cell Signaling & Molecular Targets in Cancer. Ed(s) Chatterjee M, Kashfi K, 37-49, 2012.

Books (edited and written) N/A Letters to the Editor N/A Manuals, Teaching Aids, Other Teaching Publications N/A Other Publications N/A EDITORIAL AND REVIEW ACTIVITIES Editor/Service on Editorial Board(s) Editor/Service, Clinical Pharmacology, 2010 Editoral Service, Gene Therapy and Molecular Biology, 2010 Editor/Service, J Experimental Pharmacology, 2010 Editor/Service, Journal of Biomedicine and Biotechnology, 2010 Member of Editorial Review Board N/A Journal Reviewer Ad hoc Journal Reviewer, Biochem. Biophys. Research Communications, 2007−present Ad hoc Journal Reviewer, Biochemistry, 2007−present

Ad hoc Journal Reviewer, Biotechnology and Bioengineering, 2007−present Ad hoc Journal Reviewer, Cancer Letter, 2007−present Ad hoc Journal Reviewer, Carcinogenesis, 2007−present Ad hoc Journal Reviewer, Cell Regulation, 2007−present Ad hoc Journal Reviewer, Chromosoma, 2007−present Ad hoc Journal Reviewer, Clinical Cancer Research, 2007−present Ad hoc Journal Reviewer, Experimental Cell Research, 2007−present Ad hoc Journal Reviewer, Journal Biological Chemistry, 2007−present Ad hoc Journal Reviewer, Journal of Cell Physiology, 2007−present Ad hoc Journal Reviewer, Journal of Pharmacology and Experimental Therapeutics, 2007−present Ad hoc Journal Reviewer, Molecular Carcinogenesis, 2007−present Ad hoc Journal Reviewer, Molecular Pharmacology, 2007−present Ad hoc Journal Reviewer, Nucleic Acid Research, 2007−present Ad hoc Journal Reviewer, Oncogene, 2007−present Ad hoc Journal Reviewer, Proceeding of National Academy of Sciences of U. S. A., 2007−present Ad hoc Journal Reviewer, Redox Report, 2007−present Ad hoc Journal Reviewer, Toxicological Sciences, 2007−present Ad hoc Journal Reviewer, Antioxidant and Redox Signaling, 2011−present Ad hoc Journal Reviewer, Biochemical Pharmacology, 2011−present Ad hoc Journal Reviewer, Cancer Research, 2011−present Other Editorial and Review Activities

N/A TEACHING Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center Formal Teaching Courses Taught Instructor, Research in Biomedical Sciences, GSBS, Course Number: 4.61.5 Summer, 1980 Summer, 1982 Instructor, Special Project in Biomedical Science, GSBS, Course Number: 4.61.9 Summer, 1980 Instructor, Human Genetics III, GSBS, Course Number: 11.03.3 Spring, 1983 Spring, 1986 Instructor, Molecular Biology of Oncogenes, GSBS, Course Number: 4.01.34 Spring, 1988 Spring, 1989 Fall, 1991 Fall, 1992 Fall, 1993 Fall, 1994 Fall, 1995 Fall, 1996 Fall, 1997 Instructor, Biochemistry, GSBS, Course Number: 3.00.16 Fall, 1991 Fall, 1992 Instructor, Human Gene Therapy, GSBS, Course Number: 4.01.53 Spring, 1998 Instructor, Mechanisms in Cancer Therapeutics, GSBS, Course Number: GS04-0213 Spring, 2003−present Training Programs Instructor, Biology Training Program 1979−present Instructor, Molecular Pathology Training Program 1998−present Other Formal Teaching N/A Supervisory Teaching Committees Advisory Committees Member, Thesis Advisory Committee, GSBS, Cheng Peng, 1981−1983

Member, Thesis Advisory Committee, GSBS, Chi-Cheng Luo, 1983−1985 Member, Thesis Advisory Committee, GSBS, David Krizman, 1983−1985 Member, Thesis Advisory Committee, GSBS, Julie Sanford, 1983−1987 Member, Thesis Advisory Committee, GSBS, Barbara Boggs, 1985−1987 Member, Thesis Advisory Committee, GSBS, Huang Peng, 1985−1987 Member, Thesis Advisory Committee, GSBS, Kathy Barr, 1985−1988 Member, Thesis Advisory Committee, GSBS, Bih-Chen Hwang, 1987−1990 Member, Thesis Advisory Committee, GSBS, Duane-Hwa Yen, 1987−1990 Member, Thesis Advisory Committee, GSBS, Xiao Yan Zhao, 1987−1990 Member, Thesis Advisory Committee, GSBS, Rong-Lang Yen, 1989−1992 Member, Thesis Advisory Committee, GSBS, Angobia Martin, 1991−1993 Member, Thesis Advisory Committee, GSBS, Francis Kwamin, 1991−1993 Member, Thesis Advisory Committee, GSBS, Kaushik Kundu, 1991−1994 Member, Thesis Advisory Committee, GSBS, Rong-Long Yen, 1992−1994 Member, Thesis Advisory Committee, GSBS, Wei Yu, 1993−1995 Member, Thesis Advisory Committee, GSBS, Youming Xie, 1993−1996 Member, Thesis Advisory Committee, GSBS, Siqing Fu, 1994−1996 Member, Thesis Advisory Committee, GSBS, Susan Hwang, 1994−1997 Member, Thesis Advisory Committee, GSBS, Yujiao Zhao, 1994−1997 Member, Thesis Advisory Committee, GSBS, Xinhui Zhou, 1995−1997 Member, Thesis Advisory Committee, GSBS, Jack Chen, 1995−1998

Member, Thesis Advisory Committee, GSBS, Wei-Ping Lee, 1997−2000 Member, Thesis Advisory Committee, GSBS, Bing Zheng, 1998−2000 Member, Thesis Advisory Committee, GSBS, Zhenming Yu, 1998−2003 Member, Thesis Advisory Committee, GSBS, Yu-Ye Wen, 2003 Member, Thesis Advisory Committee, GSBS, Hsu-Ping Kuo, 2005−present Member, Thesis Advisory Committee, GSBS, Liu Mo, 2009 Supervisory Committees Member, Supervisory Committee, GSBS, James Hawker, 1983 Member, Supervisory Committee, GSBS, Barbara Boggs, 1987−1990 Member, Supervisory Committee, GSBS, Bih-Chen Hwang, 1987−1990 Examining Committees Member, Candidacy Examining Committee, GSBS, Bih-Chen Hwang, 1990 Member, Candidacy Examining Committee, GSBS, Youming Xie, 1995 Member, Candidacy Examine Committee, GSBS, Yujiao Zhao, 1995 Member, Candidacy Examining Committee, GSBS, Siqing Fu, 1996 Member, Candidacy Examining Committee, GSBS, Shiaw-Yih Lin, 1998 Member, Candidacy Examining Committee, GSBS, Wei-Ping Lee, 1999 Member, Candidacy Examining Committee, GSBS, Wen-Shu Wu, 2000 Member, Candidacy Examining Committee, GSBS, Ryan von Lindern, 2002 Member, Candidacy Examining Committee, GSBS, Zhenming Yu, 2003 Member, Candidacy Examining Committee, GSBS, Yu-Ye Wen, 2006

Member, Candidacy Examining Committee, GSBS, Hsu-Ping Kuo, 2009 Member, Candidacy Examining Committee, GSBS, Wen-Hsuan Yu, 2011 Direct Supervision Undergraduate and Allied Health Students Summer Intern, The University of Texas M. D. Anderson Cancer Center, Meredith Prescott Morgan, 2011 Medical Students N/A Graduate Students Tutorial, Fall, Mark E. Reid, 1974 Tutorial, Fall, Chun-Wen Lee, 1978 Tutorial, Fall, Cheng Peng, 1979 Tutorial, Spring, Jim Hawker, 1981 Trainee, Summer, Kimberly Curyn, 1981 Tutorial, Fall, Larry Teeter, 1981 GSBS, Larry Teeter, 1982−1987 Tutorial, Fall, Amy Ader, 1983 Tutorial, Spring, Chi-Cheng Luo, 1983 Trainee, Summer, David Gray, 1983 Tutorial, Spring, David Krizman, 1983 Trainee, Summer, Ellen D. deVere, 1983 Trainee, Summer, Bernice Uycura, 1984

Trainee, Summer, Parul Patel, 1984 Tutorial, Summer, Huang Peng, 1985 Tutorial, Fall, Renee von Toerne, 1985 GSBS, Daijun Li, 1986−1989 Tutorial, Spring, Daijun Li, 1986 Trainee, Summer, Manish Assar, 1986 Trainee, Summer, Renee Freim, 1987 Chang-Ping Zou, 1988−1989 GSBS, Hong Zhang, 1988−1989 Tutorial, Summer, Hong Zhang, 1988 Trainee, Summer, Matthews Byers, 1988 Trainee, Summer, Robert Atkinson, 1988 Tutorial, Spring, Tze-Cheng Cheng, 1990 Trainee, Summer, Irwin Lee, 1991 Trainee, Summer, Jerry Donovan, 1991 GSBS, Kerry Gunning, 1992−1993 GSBS, Ge Zhou, 1992−1998 Trainee, Summer, Mark Estes, 1992 Trainee, Spring, Richard Kuo, 1992 Tutorial, Spring, Yingshuang Tao, 1994 GSBS, Irving Pass, 1997−1999

Tutorial, Winter, Lei Deng, 1997 Trainee, Summer, Sher-Lu Pai, 1997 Tutorial, Spring, Ryan von Lindern, 1998 Tutorial, Fall, Xiayang Wang, 1999 Tutorial, Fall, Diaren Xia, 2000 GSBS, Diaren Xia, 2001−2002 Trainee, Summer, Erica Wolfe, 2001 Intern, Summer, Lily Wu, 2004 GSBS, Deon Uffort, 2005−2006 Graduate Trainee, Isamu Aiba, 2006−2008 GSBS, Victoria Mdoe, 2007−2009 non-GSBS student, Mei-Yi Lee, 2009−2010 non-GSBS student, Yu-Shi Lin, 2010 non-GSBS student, Dujuan, Wang, 2013 Postdoctoral Research Fellows Swaroop Sudhakar, Ph.D., Ph.D., 1981−1982 Ramadasan Kuttan, Ph.D., Ph.D., 1982−1983 Jenny Pao, Ph.D, 1982−1984 Subrata Sen, Ph.D., 1982−1985 De-Gao Chen, Ph.D., 1983−1984 Shi-ichiro Atsumi, M.D., 1984−1986

Yu-Lin Sun, Ph.D., 1985 Tapas Mukhopadhyay, Ph.D., 1985−1988 Hyung Ju Shin, Ph.D., 1987−1988 Larry Teeter, Ph.D., 1987−1989 Shunji Kohnoe, Ph.D., 1987−1989 Qi-Hui Huang, Ph.D., 1988−1990 Masahide Ikeguchi, M.D., 1988−1991 Tien-en Chang, Ph.D., 1989−1990 Ji-ying Zao, Ph.D., 1990−1993 Rajagopal Sriram, Ph.D., 1992−1993 Zhi-Ming Ding, Ph.D., 1992−1994 Yumi Yamaguchi, M.D., Ph.D., 1993−1995 Jia-Ju Bao, Ph.D., 1994−1996 Yoshiaki Yamane, M.D., 1995−1997 Masato Furuichi, Ph.D., 1996−1997 Yangjun Qin, Ph.D., 1998−1999 Shigeru Tatebe, M.D., Ph.D., 1998−2001 Zeshing Liu, M.D., Ph.D., 1999−2001 Hitoshi Unate, M.D., Ph.D., 2001−2003 Peiman Liu, M.D., 2002−2005 Im-Sook Song, Ph.D., 2003−2006

Min-Koo Choi, Ph.D., 2005−2006 Tony Tung-Yin Lee, M.D., 2005−2006 Soo-Yong Lee, Ph.D., 2005−2008 Bal Mukund Mishra, PhD, 2007−2008 Jeong-Ran Park, 2010−2012 Wen Jiang, 2012−2013 Clinical Residents and Fellows Reupen Dekmezian, M.D., 1985−1987 Other Supervisory Teaching Subrata Sen, Ph.D., Research Associate, Research Associates, 1985−1988 Larry D. Teeter, Ph.D., Research Associate, Research Associate, 1989−1994 William Schilling, Ph.D., Visiting Scholar, Visiting Scholars, Baylor College of Medicine, Houston, TX, 1992−1993 Cheng-Yang Chou, M.D., Visiting Scholar, Visiting Scholars, National Cheng Kung University, Taiwan, 1994−1995 Osamu Kimura, Visiting Scholar, Visiting Scholars, Tottori University, Yonago, Japan, 1994−1995 Terrence Kirley, Ph.D., Visiting Scholar, Visiting Scholars, University of Cininnati, Ohio, 1994 Akira Gomi, M.D., Ph.D., Visiting Scholar, Visiting Scholars, Jichi University, Tochigi, Japan, 1996−1997 Seiichi Nagamura, Visiting Scholar, Visiting Scholars, Tottori University, Yonago, Japan, 1996−1997 Jia-Ju Bao, M.D., Research Associate, Research Associate, 1996−1999 Yen-Chiu Lin-Lee, Ph.D., Research Associate, Research Associate, 1996−2002 Yoji Ikegami, M.D., Visiting Scholar, Visiting Scholars, Meiji College of Pharmacy, Tokyo, Japan, 1997−1998 Ying-jie Wei, Ph.D., Visiting Scholar, Visiting Scholar, Beijing Medical College, People Republic of China, 1999−2001

Yingjie Wei, Ph.D., Research Associate, Research Associate, 2001−2005 Xinlin Yang, Ph.D., Visiting Scholar, Visiting Scholars, Beijing Institute of Technology, People's Republic of China, 2004−2005 Anwar Hossain, Ph.D., Instructor, Ph.D., Research Associate/Instructor, 2005−2008 LeRoy Morgan, M.D., Ph.D., Visiting Scholar/Professor, Visiting Scholar, Louisiana State University, School of Medicine, New Orleans, LA, 2005−present Helen H. W. Chen, M.D., Visiting Scholar, Visiting Scholars, National Cheng-Kung University, Tainan, Taiwan, 2006−2007 Zheng D. Liang, Ph.D., Instructor, 2006−2011 XiaoXing Guan, M.D., Ph.D., Visting Scholar, Visiting Scholars, Jin-Ling University, Nanjing, PRC, 2007−2008 Wen-Bin Tsai, Ph.D., Instructor, 2008−present Teaching Outside of Current Institution Formal Teaching Courses Taught N/A Training Programs N/A Other Formal Teaching N/A Supervisory Teaching Committees Advisory Committees Member, Thesis Advisory Committee, Baylor, Sonia Mogan, 2003 Supervisory Committees

N/A Examining Committees Member, Candidacy Committee, Baylor College of Medicine, Sonia Morgan, 2007 Direct Supervision Undergraduate and Allied Health Students N/A Medical Students N/A Graduate Students N/A Postdoctoral Research Fellows N/A Clinical Residents and Fellows N/A Other Supervisory Teaching N/A CONFERENCES AND SYMPOSIA Organization of Conferences/Symposia (Include chairing session) AACR, The 84th Annual Meeting of American Association of Cancer Research, "P-glycoprotein, modulators and new developments," Orlando, FL, Session Chairman, 5/1993 Kaoshiang, Workshop, "Molecular Biology and Hepatitis and Liver Cancer," Kaoshiang, Organizer and Lecturer, 6/1995 Presentations at National or International Conferences

Invited Antibiotic Mediated Fragmentation of DNA, Size limits and Characterization of the Degradation Products, Biophysical Society Meeting, Columbus, OH, 3/1/1973 Localization of Human Satellite DNA, American Society of Biological Chemists, Atlantic City, NJ, 4/1/1975 Dissolution of Mammalian Chromosomes and Preferential Euchromatin Damage Induced by Bleomycin, American Society for Cell Biology, San Juan, Puerto Rico, 11/1/1975 Effects of Protein Synthesis by Bleomycin in a Cell free System from Wheat Germ Embryo, Federation of American Societies for Experimental Biology, Anaheim, CA, 4/1/1976 In Situ Hybridization Evidence for the Lack of Messenger Synthesis Activity in the Heterochromatic Areas of Chromosomes, The First International Congress on Cell Biology, Boston, MA, 9/1/1976 Localization of Mammalian mRNA Sequences on Metaphase Chromosome, The First International Congress on Cell Biology, Boston, MA, 9/1/1976 The Distribution of DNA-Tightly Bound Proteins in Chicken Ovalbumin Gene and Its Flanking DNA Sequences, The Second International Congress on Cell Biology, West Berlin, Germany, 9/1/1980 Possible Amplification of Gene Coding for a Low Molecular Weight Protein in the Vincristine-Resistant Chinese Hamster Ovary Cells, American Association for Cancer Research Southwest Section, Houston, TX, 2/1/1981 Organization of the Structural Genes in Metaphase Chromosomes, The First Annual Congress on Recombinant DNA Research, San Francisco, CA, 3/1/1981 Actions of Antitumor Drug Bleomycin on Chromatin Structures Altered Gel Electrophoretic Mobility of Bleomycin-Mediated Release of Nucleosomal DNA and Preferential Damage of Active Chromatin by Bleomycin, 72nd Annual Meeting of the American Association for Cancer Research, Washington, DC, 4/1/1981 Actions of Antitumor Drug Bleomycin on Chromatin Structure, Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics, Calgary, Canada, 8/1/1981 Albumin and Alpha-Fetoprotein Genes in Hepatocellular Carcinomas, Restriction Fragment Polymorphism and DNA Methylation, Thirty-fifth Annual Symposium on Fundamental Cancer Research, Houston, TX, 3/1/1982 DNA Sequences Associated with Nuclear Matrix, Chromosomal Scaffold and Synaptonemal Complex, UCLA Symposium on Gene Regulation, Denver, CO, 8/1/1983 Chromatin Structure of the Chicken b-Tubulin Gene, Annual Meeting of American Society of Cell Biology, San Antonio, TX, 11/1/1983 The Expression and Chromatin Structure of Chicken Glyceraldehyde-3-Phosphate Dehydrogenase Gene in Mouse Cells, Annual Meeting of American Society of Cell Biology, San Antonio, TX, 11/1/1983 Vincristine-Resistant Chinese Hamster Ovary Cells, Cold Spring Harbor Meeting on "Gene Amplification and Aberrant Chromosomes," Cold Spring, NY, 11/1/1983 Special Symposium on "Chromosome Aberration and DNA Repair," Varansi, India, 12/1/1983 Chromatin Structure of the Chicken Glyceraldehyde-3-Phosphate Dehydrogenase Gene, Gordon Research Conference, Tilton School, NH, 7/1/1984 The Expression and Chromatin Structure of the Chicken Glyceraldehyde-3-Phosphate Dehydrogenase Gene in Mouse Cells, The Third International Congress on Cell Biology, Tokyo, Japan, 8/1/1984 DNA Amplification in Multidrug Chinese Hamster Ovary Cells, The l3th International Congress of Biochemistry, Amsterdam, 8/1/1985

Multidrug Resistant Chinese Hamster Ovary Cells, National Institutes of Health, Cancer Research Special Workshop on Molecular and Cellular Biology of Drug Resistance in Animal Cells, Bethesda, MD, 9/1/1985 Loss of Tumorigenicity in Multidrug Resistant NIH 3T3 Cells Transformed with C-erb2/Neu Oncogene, 79th Annual Meeting of the American Society for Cancer Research, New Orleans, LA, 5/1/1988 Consistent DNA Rearrangement in Multidrug Resistant Cells, 14th International Congress on Biochemistry, Prague, 7/1/1988 Characterization of DNA Sequences in the Recombination Hotspot in the Chinese Hamster mdr locus, The 2nd meeting on drug-resistance and cancer chemotherapy, Bethesda, MD, 4/1/1989 Regulation of mdr gene expression in drug resistance variants, Fifthteenth International Congress Biochemistry and Molecular Biology, Jerusalem, 7/1/1989 Single-stranded DNA binding proteins recognize DNA sequences capable of adopting non-B configuration at the promoter region of the chicken b2-Tublulin gene, Cold Spring Harbor Meeting, Cold Spring, NY, 9/1/1989 Tissue-Specific Expression of Multidrug Resistance (mdr) Genes, The 14th Annual Meeting Texas Pharmacologist, San Antonio, TX, 3/1/1990 Hepatocarcinogenesis and mdr gene expression, Western pharmacological society meeting, Acapulco, Mexico, 2/1/1991 Expression of MDRl gene in human hepatocellular carcinoma, The Third International Symposium on Viral Hepatitis and Hepatocellular Carcinoma, Taipei, 12/1/1991 Activation of multidrug resistance (P-glycoprotein) gene during the development of hepatocellular carcinoma in human hepatitis B virus transgenic mice, FASEB summer conference, Snowmass, CO, 7/1/1992 Regulation of Multidrug Resistance mdrlb/mdrl gene expression in primary uterine epithelial cell culture, The 8th International Conference of the International Society of Differentiation, Hiroshima, Japan, 10/1/1994 "Molecular and Cellular Biology of Hepatocellular Carcinomas," "Approaches to Gene Therapy of Hepatocellular Carcinoma," Kaoshiung Medical College, Kaohsiung, 6/1/1995 Molecular and Cellular Biology of Hepatocellular Carcinoma, "Gene Regulation and Hepatocarcinogenesis," Kaohsiung, 6/1/1995 Hepatic Gene Therapy Using a Novel Receptor, The Second Annual Meeding on Artifical Self-Assembling Systems for Gene Transfer, Boston, MA, 9/1/1995 Hepatic gene targeting/therapy using a novel ligand from a malaria parasite protein, International Conference on Gene Therapy and Molecular Biology, Crete, Greece, 8/1/1998 Chromosomal Fragile Sites and DNA Amplification in Drug-Resistant Cells, NCI Sponsored Fragile Site Consortium Meeting, Rochester, MN, 9/1/1998 The Roles of Reactive Oxygen Species in Hepatocarcinogenesis and Liver Cancer Gene Therapy, Japanese Society of Gastroenterology, Yonago, Japan, 6/1/2001 "Cell Biology of Metals," "Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells," Gordon Research Conference, Bates College, ME, 7/1/2005 Evolution of Drug Resistance in Cancer Chemotherapy, The 1st International Conference of Regenerative Medicine and Biomedical Medicine, Jin-Nan University, China, 2010 Overcoming Cisplatin-Resistance by Cooper-Lowering Agents, The 11th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy, Italy, 10/11/2012 Other, Including Scientific Exhibitions

"Molecular Therapeutics of Cancer," Redox regulation of argininosuccinate synthetase expression and implications to the development of resistance to arginine deaminase inhibitor," Gordon Research Conference, Corby-Sawyer College, NH, 7/2007 The Roles of Sp1 in Transcriptional Regulation of Copper Transporter Expression, Gordon Research Conference - 2008 Program, Mechanisms of Toxicity, Bates College, Lewiston, ME, 7/27/2008 Induction of Argininosuccinate Synthetase Expression by Arginine Depletion Activates P13K/Akt/c-Myc Pathway and Confers Arginine Deiminase Resistance in Melanoma, The 9th International Congress on Cell Biology, In Conjunction with the 20th Annual Meeting of the Korean Society for Molecular and Cellular Biology, Coex, Korea, Republic of, 10/7/2008 A Novel Anti-Hepatitis C Strategy for Hepatocellular Carcinoma Prevention, Hong Kong Cancer Institute AACR International Conference on Infection and Cancer: Biology, Therapeutics, and Prevention, China, 11/29/2008 Mechanistic Comparison of Human High-Affinity Copper Transporter 1 (hCtr1)-Mediated Transport between Copper Ions and Cisplatin, Gordon Research Conference, Cell Biology of Metals, Newport, RI, 8/2009 Regulation Mechanisms of Copper Homeostasis in Mammalian Cells, Gordon Research Conference, Switzerland, 2011 Seminar Invitations from Other Institutions Effects of Bleomycin on Mammalian Chromosomes, Texas Medical Association, Houston, TX, 5/1/1975 Action of Bleomycin on Chromatin, The Academia Sinica, Taipei, 11/1/1977 Action of Antitumor Drugs on Chromatin Structure, Vrije Universiteit, Brussel, Belgium, 4/1/1979 Action of Antitumor Drug on Chromain, University of Nunberg-Erlangen, 7/1/1979 Chromatin Structure of the Chicken Ovalbumin Gene, Laboratoire de Moleculaire Genetique des Eukaryote, Strousbourg, France, 9/1/1979 Organizatoin of the Structural Genes in Metaphases Chromosomes, The University of Texas Health Science Center at H, Houston, TX, 1/1/1981 Organization of the Structural Genes in Metaphase Chromosomes, Wadley Institute of Molecular Medicine, Dallas, TX, 2/1/1981 Action of Therapeutic Agent on Chromatin, Smithkline Corporation, Philadelphia, PA, 1/1/1982 Chromatin Structure of Eukaryotic Genes, Univ. of North Carolina, Chappel Hill, NC, 2/1/1982 Vincristine-Resistant Chinese Hamster Ovary Cells, Stanford University, Stanford, CA, 8/1/1982 Multidrug Resistance in Animal Cells and Human Tumor Institute of Biomedical Sciences, Scademia Sinca, Taipei, 8/1/1987 Drug Resistance and Cancer Chemotherapy, University of Texas Health Science Center, Medical, Houston, TX, 12/1/1988 Multidrug resistance gene family of liver cancers, National Taiwan University, College of Medicine, Taipei, 12/1/1991 Regulation of MDR gene expression, Academia Sinica, Taipei, 12/1/1991

Tulane University, New Orleans, LA, 10/1/1992 Regulation of MDR gene expression during tumor progression, Graduate School of Biomedical Science, Houston, TX, 10/1/1993 Approaches to gene therapy of liver cancers, Tottori University, Yonago, Japan, 10/1/1994 The role of chromosome fragile site in DNA Amplification in Mammalian Cells, Texas A and M University, College Station, TX, 9/1/1995 Approaches to for gene therapy of liver cancers, University of Miami, Miami, FL, 3/1/1996 The evolution of drug resistance in cancer and it implication for gene therapy of liver cancers, University of Texas Health Science Center Medical, Houston, TX, 3/1/1997 The evolution of drug resistance in cancer and its implication for gene therapy of liver cancers, The University of Tennessee at Memphis, Memphis, TN, 11/1/1997 The Roles of Reactive Oxygen Species in Hepatocarcinogenesis and Liver Cancer Gene Therapy, Miami, FL, 5/1/2001 Evolution of Drug-Resistance in GI Cancers, Indiana University Cancer Center, Indianapolis, IN, 4/1/2005 A Novel Drug Resistance in Cancer Chemotherapy, Tokyo Institute of Technology, Yokohama, Japan, 2/2006 Evolution of Drug Resistance in Cancer Chemotherapy, Tokyo Institute of Technology, Yokohama, Japan, 2/2006 Evolution of Drug-Resistance in GI Cancers, Tokyo Institute of Technology, Yokohama, Japan, 2/2006 Identification of A Novel Fragile Site Associated (fsa) Gene in the Murine Embryonic Development, Kaoshiung Medical University, Kaoshiung, Taiwan, 6/2007 Redox Regulation of Drug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities, National Cheng Kung University, Tainan, Taiwan, 6/2007 Invited Speaker, Elevated expression of Glutathione by Transfection Confers Cellular Sensitivity to Cisplatin, The Xth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy, Verona, Italy, 11/1/2007 Redox Regulation of Drug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunity, National Health Research Institute, Ma-Li, Taiwan, 12/21/2007 Roles of Transcription Factor Sp1 in the Regulation of Heavy Metal Transporters, National Medical University, 12/31/2007 The Development of Hepatic Targeting Therapy of Hepatocellular Carcinomas and Hepatitis, Development Center for Biotechnology, Taipei, Taiwan, 1/2/2008 Evolution of Drug Resistance in Cancer Chemotherapy, The 1st International Conference of Regenerative Medicine and Biomedical Medicine, Jin-Nan University, China, 5/2010 New Insights into Recent Platinum Drug Development in Cancer Research, National Cheng Kung University, Taiwan, 3/18/2011 Targeted Cancer Metabolism Therapy of Malignant Melanoma by Arginine Deprivation Strategy, Melanoma and Skin Cancer Program Seminar, The University of Texas M. D. Anderson Cancer Center, 11/1/2012

Lectureships and Visiting Professorships Xiamen University, Fujian, China, 1/1/1983 Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 2006 National Cheng Kung University, 2007 National Cheng Kung University, 2013

Other Presentations at State and Local Conferences N/A PROFESSIONAL MEMBERSHIPS/ACTIVITIES Professional Society Activities, with Offices Held National and International American Association for the Advancement of Science Regular Member, 1986−1989 American Society for Cell Biology Member, 1986−1988 American Society of Biological Chemists Member, 1988−1995 American Association of Cancer Research Regular Member, 1991−2009 Emertius Member, 2009−present Local/State N/A UNIQUE ACTIVITIES N/A DATE OF LAST CV UPDATE 12/19/2012 Macus T. Kuo, Ph.D.